Abstract
Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has b......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
